Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Duke University
Novartis
Information provided by (Responsible Party):
David F. McDermott, MD, Beth Israel Deaconess Medical Center
ClinicalTrials.gov Identifier:
NCT00827359
First received: January 21, 2009
Last updated: October 3, 2014
Last verified: October 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: January 2016
  Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)